Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C14H15FN2.ClH |
| Molecular Weight | 266.742 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CCC1(CC2=C(C1)C=C(F)C=C2)C3=CNC=N3
InChI
InChIKey=XAGTWPPXXHAZMK-UHFFFAOYSA-N
InChI=1S/C14H15FN2.ClH/c1-2-14(13-8-16-9-17-13)6-10-3-4-12(15)5-11(10)7-14;/h3-5,8-9H,2,6-7H2,1H3,(H,16,17);1H
| Molecular Formula | C14H15FN2 |
| Molecular Weight | 230.2807 |
| Charge | 0 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Fipamezole is a fluorine substituted imidazole compound with high antagonist specificity for the presynaptic alpha2-adrenoceptor. There were no significant differences between the affinity of Fipamezole for the different subtypes, thus characterizing Fipamezole as a non-subtype–selective alpha2 antagonist. Fipamezole had been in phase III clinical trials for the treatment of dyskinesia associated with Parkinson’s disease. Detected side effects are hypertension, nausea, vomiting, dysgeusia, facial flushing.
CNS Activity
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL1867 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12889076 |
9.2 nM [Ki] | ||
Target ID: CHEMBL1942 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12889076 |
17.0 nM [Ki] | ||
Target ID: CHEMBL1916 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12889076 |
55.0 nM [Ki] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Therapeutic strategies to prevent and manage dyskinesias in Parkinson's disease. | 2015-02 |
|
| Non-dopaminergic treatments for motor control in Parkinson's disease. | 2013-09 |
|
| [Pharmacotherapy of Parkinson's disease: progress or regress?]. | 2013-07-24 |
|
| Randomized clinical trial of fipamezole for dyskinesia in Parkinson disease (FJORD study). | 2012-07-10 |
|
| The α₂ adrenergic antagonist fipamezole improves quality of levodopa action in Parkinsonian primates. | 2010-10-15 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT00559871
30 mg, 60 mg or 90 mg three times per day for up to 28 days
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/12889076
Fipamezole had moderate affinity for histamine H1 and H3 receptors and the serotonin (5-HT) transporter (IC50s between 100 nM and 1 uM).
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 21:25:34 GMT 2025
by
admin
on
Mon Mar 31 21:25:34 GMT 2025
|
| Record UNII |
441J9148CQ
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
441J9148CQ
Created by
admin on Mon Mar 31 21:25:34 GMT 2025 , Edited by admin on Mon Mar 31 21:25:34 GMT 2025
|
PRIMARY | |||
|
150586-72-4
Created by
admin on Mon Mar 31 21:25:34 GMT 2025 , Edited by admin on Mon Mar 31 21:25:34 GMT 2025
|
PRIMARY | |||
|
6918257
Created by
admin on Mon Mar 31 21:25:34 GMT 2025 , Edited by admin on Mon Mar 31 21:25:34 GMT 2025
|
PRIMARY |